Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated?

Robert P Finger and Robyn H Guymer
Med J Aust 2013; 198 (5): . || doi: 10.5694/mja12.11295
Published online: 18 March 2013

To the Editor: Neovascular age-related macular degeneration (NVAMD) is the most common cause of blindness in Australia.1 Current treatment to prevent further deterioration in vision, and an improvement in some, involves the antivascular endothelial growth factor (anti-VEGF) agents ranibizumab (Lucentis, listed on the Pharmaceutical Benefits Scheme [PBS] since August 2007) or bevacizumab (Avastin, used off-label for NVAMD).2

  • Robert P Finger
  • Robyn H Guymer

  • Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, VIC.


Competing interests:

Robert Finger has received payment from Novartis for work on an expert statement on treatment of angioid streaks, and from Opthea for work on clinical trials design. Robyn Guymer has received a fellowship and payment for work on advisory boards from Novartis and Bayer, and a travel grant from Novartis.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.